Celgene Corp (NASDAQ:CELG)

78.37
Delayed Data
As of May 18
 -1.61 / -2.01%
Today’s Change
78.35
Today|||52-Week Range
147.17
-24.90%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$61.8B

Company Description

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Contact Information

Celgene Corp.
86 Morris Avenue
Summit New Jersey 07901
P:(908) 673-9000
Investor Relations:
(908) 673-9969

Employees

Shareholders

Other institutional38.31%
Mutual fund holders37.97%
Individual stakeholders1.28%

Top Executives

Mark J. AllesChairman, President, CEO & COO
Peter N. KelloggExecutive VP, Chief Financial & Accounting Officer
Jay T. BackstromChief Medical Officer
Rupert J. VesseyPresident-Research & Early Development
Joseph S. CamardoSenior Vice President-Global Medical Affairs